227 related articles for article (PubMed ID: 37334428)
1. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
[TBL] [Abstract][Full Text] [Related]
2. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
4. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
7. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
[TBL] [Abstract][Full Text] [Related]
8. Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases.
Segura Fábrega A; Pérez Catalán I; Gómez Alfaro I; García Muñoz S; Roig Martí C; Rodríguez Lozano N; Folgado Escudero S; Varea Villanueva M; Gascón Buj A; Torres García M; Reig Valero R; Ferrando Piqueres R; Usó Blasco J
Rev Esp Quimioter; 2023 Dec; 36(6):655-657. PubMed ID: 37786958
[TBL] [Abstract][Full Text] [Related]
9. Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients.
Pérez Catalán I; García Muñoz S; Roig Martí C; Gómez Alfaro I; Serrano Picazo L; Torres García M; Reig Valero R; Ferrando Piqueres R; Mateu Campos L; Ramos Rincón JM; Usó Blasco J
Rev Esp Quimioter; 2022 Dec; 35(6):589-591. PubMed ID: 36250675
[No Abstract] [Full Text] [Related]
10. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
[TBL] [Abstract][Full Text] [Related]
11. Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: A real-life experience.
Caso JM; Fernández-Ruiz M; López-Medrano F; Caro-Teller JM; Lizasoain M; San-Juan R; Fayos Pérez M; Rodríguez-Goncer I; Silva JT; Aguado JM
J Med Virol; 2023 Sep; 95(9):e29082. PubMed ID: 37671852
[TBL] [Abstract][Full Text] [Related]
12. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
Ford ES; Simmons W; Karmarkar EN; Yoke LH; Braimah AB; Orozco JJ; Ghiuzeli CM; Barnhill S; Sack CL; Benditt JO; Roychoudhury P; Greninger AL; Shapiro AE; Hammond JL; Rusnak JM; Dolsten M; Boeckh M; Liu C; Cheng GS; Corey L
Clin Infect Dis; 2023 Mar; 76(5):926-929. PubMed ID: 36326680
[TBL] [Abstract][Full Text] [Related]
14. Nirmatrelvir Resistance-de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure-a Case Report.
Zuckerman NS; Bucris E; Keidar-Friedman D; Amsalem M; Brosh-Nissimov T
Clin Infect Dis; 2024 Feb; 78(2):352-355. PubMed ID: 37596935
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study.
Basoulis D; Tsakanikas A; Gkoufa A; Bitsani A; Karamanakos G; Mastrogianni E; Georgakopoulou VE; Makrodimitri S; Voutsinas PM; Lamprou P; Kontos A; Tsiakas S; Gamaletsou MN; Marinaki S; Sipsas NV
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515201
[TBL] [Abstract][Full Text] [Related]
16. Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab.
Gentile I; Foggia M; Silvitelli M; Sardanelli A; Cattaneo L; Viceconte G
Virol J; 2023 Dec; 20(1):301. PubMed ID: 38102675
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
[TBL] [Abstract][Full Text] [Related]
20. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]